Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05872828
Other study ID # SBRE-22-0307
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date April 1, 2023
Est. completion date April 30, 2024

Study information

Verified date November 2023
Source The Nethersole School of Nursing
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The goal of this cross-sectional study is to investigate the prevalence and risk factors of anxiety and depression and their relationships with immune functions and quality of life among liver cancer patients in the COVID-19 pandemic era. The objectives of this study are: 1. To examine the prevalence of anxiety and depression among patients with liver cancer during the COVID-19 pandemic. 2. To identify risk factors associated with anxiety and depression among these patients. 3. To determine the association between anxiety, depression, immune function, and quality of life among liver cancer patients. Participants will be asked to fill a digital questionnaire.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
Observational study. No intervention will be adopted.

Locations

Country Name City State
China Zhuhai People's Hospital Zhuhai Guangdong

Sponsors (1)

Lead Sponsor Collaborator
The Nethersole School of Nursing

Country where clinical trial is conducted

China, 

References & Publications (16)

See more »

Outcome

Type Measure Description Time frame Safety issue
Primary Anxiety score Participants' anxiety status with HADS Baseline
Primary Depression score Participants' depression status with HADS Baseline
Secondary Quality of life score (The EORTC QLQ-C30) The European Organization for Research and Treatment of Cancer(EORTC) Quality of Life Questionnaire results. Scores range from 0 to 100. A higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms. Baseline
Secondary Quality of life score (The EORTC QLQ-HCC18) The Hepatocellular Carcinoma Module of The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Scores range from 0 to 100. A higher score represents a high level of symptomatology or problems. Baseline
Secondary Immune variables 1 White blood cell counts (WBC). Collected from daily medical records. Baseline
Secondary Immune variables 2 Total neutrophil count. Collected from daily medical records. Baseline
Secondary Immune variables 3 Total lymphocyte count. Collected from daily medical records. Baseline
Secondary Immune variables 4 Total monocyte count. Collected from daily medical records. Baseline
Secondary Immune variables 5 Neutrophilic granulocyte percentage. Collected from daily medical records. Baseline
Secondary Immune variables 6 Percentage of lymphocytes. Collected from daily medical records. Baseline
Secondary Immune variables 7 Monocyte percentage. Collected from daily medical records. Baseline
Secondary Immune variables 8 C-reactive protein (CRP). Collected from daily medical records. Baseline
See also
  Status Clinical Trial Phase
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Recruiting NCT05160740 - Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer N/A
Completed NCT01906021 - Study of New Software Used During Ablations N/A
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Recruiting NCT05953337 - Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) N/A
Enrolling by invitation NCT04466124 - Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT03059238 - Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure Phase 3
Recruiting NCT02632188 - Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT01388101 - Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor) N/A
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Completed NCT00980239 - HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver Phase 1
Completed NCT01042041 - Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer Phase 1
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Completed NCT00543777 - Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease Phase 1/Phase 2
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A